EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1

Valeria A Sansone, Andrea Lizio iD, Carola R Ferrari Aggradi iD, Lucia C Greco, Cynthia Gagnon iD, Sub Subramony, Richard H Roxburgh, Karlien Mul iD, Johanna Hamel iD, Kate Eichinger, Man Hung iD, Jeffrey M Statland und 22 weitere

Muscle & Nerve · 2026-07 · 74 (1) · 187-197

DOI: 10.1002/mus.70277 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Muscle & Nerve, online erschienen am 11.05.2026. Verfasst von Valeria A Sansone und 33 weiteren Autor:innen. Beteiligte Einrichtung: The NeMO Clinical Center in Milan, Milan, Italy. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Psychometrics, Patient Reported Outcome Measures. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Avidity-Novartis, Dyne Therapeutics, Vertex Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aim The Myotonic Dystrophy Health Index (MDHI) is a patient‐reported outcome measure assessing disease burden in DM1. In prior cross‐sectional studies, the MDHI correlated with disability status and with several functional measures and activities of daily living. To aid its use and interpretation, we investigated the longitudinal performance of MDHI.

Methods

Patients with genetically confirmed DM1 were enrolled as part of an observational longitudinal study within the Myotonic Dystrophy Clinical Research Network (DMCRN). Internal consistency and construct validity were evaluated to confirm previous findings. Both the Minimal Detectable Change (MDC) and the Minimal Clinically Important Difference (MCID) were calculated using distribution‐ and anchor‐based methods, respectively. Sensitivity to change and responsiveness were also investigated, along with potential factors associated with the progression of overall burden.

Results

451 DM1 patients were assessed, with 147 completing 24‐month follow‐up. The MDHI showed excellent internal consistency ( α = 0.95) and confirmed construct validity. MDC for the total score ranged from ±4.24 (effect size change‐based approach) to ±9.72 (Standard Error Method‐based approach) points, while MCID ranged from small changes (−0.12 improvement/+1.25 worsening) to large changes (−2.17 improvement/+4.71 worsening). Changes in MDHI total and subscale scores were statistically significant at individual‐ or subgroup‐levels and consistently mirrored changes in corresponding clinical measures.

Discussion

The MDHI demonstrates robust sensitivity and responsiveness to individual and subgroup‐level changes in disease burden, offering valuable insights into patient‐perceived progression. These findings support MDHI use over time and as a potential additional outcome measure at subgroup levels in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyPsychometricsPatient Reported Outcome MeasuresHumansFemaleMaleLongitudinal StudiesMiddle AgedAdultActivities of Daily LivingCohort StudiesReproducibility of ResultsSeverity of Illness IndexAgedDisease ProgressionYoung Adult

Stichwörter der Autor:innen

longitudinal validitymyotonic dystrophy health indexmyotonic dystrophy type 1patient‐reported outcome measuresresponsiveness

Autor:innen und Institutionen

  • The NeMO Clinical Center in Milan, Milan, Italy.
  • Neurorehabilitation Unit, Milan, University of Milan Italy, Milan, Italy.
  • Université de Sherbrooke, CIUSSS Saguenay-Lac-St-Jean, Québec, Canada.
  • Department of Neurology, University of Florida College of Medicine, Gainesville, Florida, USA.
  • The University of Auckland, Centre for Brain Research Neurogenetics Clinic, Auckland, New Zealand.
  • Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.

ORCID-Profile: Andrea Lizio, Carola R Ferrari Aggradi, Cynthia Gagnon, Karlien Mul, Johanna Hamel, Man Hung, Benedikt Schoser, Ericka P Greene, Chad Heatwole, Nicholas E Johnson

Förderung

  • Avidity-Novartis
  • Dyne Therapeutics
  • Vertex Pharmaceuticals
  • Takeda Pharmaceuticals USA
  • PepGen
  • Sanofi
  • Pfizer
  • U.S. Food and Drug Administration

Zitieren

APA

Sansone, V. A., Lizio, A., Ferrari Aggradi, C. R., Greco, L. C., Gagnon, C., Subramony, S., Roxburgh, R. H., Mul, K., Hamel, J., Eichinger, K., Hung, M., Statland, J. M., Turner, C., Elsheikh, B., Schoser, B., Ragole, T., Matthews, E., Sampson, J., Takahashi, M. P., …, & Myotonic Dystrophy Clinical Research Network (2026). Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1. Muscle & Nerve, 74(1), 187-197. https://doi.org/10.1002/mus.70277

Vancouver

Sansone VA, Lizio A, Ferrari Aggradi CR, Greco LC, Gagnon C, Subramony S, et al. Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1. Muscle & Nerve. 2026;74(1):187-197. doi:10.1002/mus.70277

BibTeX
@article{Sansone2026,
  author = {Sansone, Valeria A and Lizio, Andrea and Ferrari Aggradi, Carola R and Greco, Lucia C and Gagnon, Cynthia and Subramony, Sub and Roxburgh, Richard H and Mul, Karlien and Hamel, Johanna and Eichinger, Kate and Hung, Man and Statland, Jeffrey M and Turner, Chris and Elsheikh, Bakri and Schoser, Benedikt and Ragole, Thomas and Matthews, Emma and Sampson, Jacinda and Takahashi, Masanori P and Wicklund, Matthew and Swenson, Andrea and Laverty, Chamindra G and Shieh, Perry and Greene, Ericka P and Beretta, Maria and Casiraghi, Jacopo L and Dekdebrun, Jeanne and Raymond, Jennifer and Langeslay, Ruby and DeSpain, Erin and Thornton, Charles A and Heatwole, Chad and Johnson, Nicholas E and Myotonic Dystrophy Clinical Research Network, Myotonic Dystrophy Clinical Research Network},
  title = {Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1},
  journal = {Muscle & Nerve},
  year = {2026},
  volume = {74},
  number = {1},
  pages = {187--197},
  doi = {10.1002/mus.70277}
}
Kostenlos starten →